NCT06682247Not yet recruiting
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in the Treatment of Microsatellite Stable Advanced Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 12 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced colorectal cancer patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 7 Nov 2024
- Start date
- 15 Nov 2024
- Primary completion date
- 15 Jun 2025
- Lead sponsor
- Feng Wang
- Diseases
- Colorectal cancer
- NCT number
- NCT06682247
What you commit to
- Study type: Observational
- Planned participants: 200
- From 15 Nov 2024 to the primary completion date, 15 Jun 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Lack of follow-up data.
- Chidamide stopped after less than two cycles.
- Serious comorbidities that interfere with the efficacy or safety analysis
Who the study is looking for
- Aged≥18 years
- Histology-confirmed metastatic CRC (mCRC);
- ECOG 0\~2
- At least one efficacy evaluation
- Life expectancy of at least 3 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.